Immunohistochemical Expression of Somatostatin Receptor Subtypes in a Panel of Neuroendocrine Neoplasias
| Autor: | Satu Maria Remes, Johanna Arola, Tiina Vesterinen, Caj Haglund, Helena Leijon |
|---|---|
| Přispěvatelé: | Department of Pathology, HUSLAB, Institute for Molecular Medicine Finland, Helsinki Institute of Life Science HiLIFE, University Management, HUS Abdominal Center, Department of Surgery, II kirurgian klinikka, CAN-PRO - Translational Cancer Medicine Program, Research Programs Unit, University of Helsinki |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Quality Control
Cytoplasm Histology TISSUES medicine.drug_class SSTR2A 030209 endocrinology & metabolism Biology Monoclonal antibody VALIDATION 03 medical and health sciences Radioligand Assay 0302 clinical medicine medicine Somatostatin receptor 2 Humans Somatostatin receptor 1 Receptors Somatostatin Receptor Tissue microarray Somatostatin receptor REASSESSMENT Cell Membrane Antibodies Monoclonal Articles TUMORS Immunohistochemistry 3. Good health somatostatin receptor Neuroendocrine Tumors Somatostatin 030220 oncology & carcinogenesis Cancer research 1182 Biochemistry cell and molecular biology Anatomy MONOCLONAL-ANTIBODIES neuroendocrine tumor |
| Zdroj: | J Histochem Cytochem |
| Popis: | Neuroendocrine neoplasias (NENs) are known to express somatostatin receptors (SSTRs) 1–5, which are G-protein-coupled cell membrane receptors. Somatostatin receptor imaging and therapy utilizes the SSTR expression. Synthetic somatostatin analogs with radioligands are used to detect primary tumors, metastases, and recurrent disease. Receptor analogs are also used for treating NENs. Furthermore, commercially available SSTR antibodies can be used for the immunohistochemical (IHC) detection of SSTRs. We investigated different SSTR antibody clones applying diverse IHC protocol settings to identify reliable clones and feasible protocols for NENs. A tissue microarray including NENs from 12 different primary sites were stained. Only UMB clones were able to localize SSTR on the cell membranes of NENs. SSTR2 (UMB1) emerged as the most common subtype followed by SSTR5 (UMB4) and SSTR1 (UMB7). SSTR3 (UMB5) expression was mainly cytoplasmic. Yet, SSTR4 expression was weak and located primarily in the cytoplasm. Thus, appropriate IHC protocols, including proper positive and negative controls, represent requirements for high-quality NEN diagnostics and for planning personalized therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|